This site is for information on the various Chemo treatments and Stem Cell Therapies since 1992. This journey became bitter sweet in 2014, with the passing of my beautiful and dear wife. Sherry, had fought Non - Hodgkins Lymphoma(NHL) since 1990, in and out of remissions time and time again. From T-Cell therapies(1990's) to Dual Cord Blood Transplant(2014), she was in Clinical Trials over the years. This site is for informational purpose only and is not to promote the use of certain therapies.
Thursday, April 16, 2015
Aeterna Zentaris files additional patent application of Zoptarelin Doxorubicin
Québec City, Canada, April 16, 2015, Aeterna Zentaris Inc. today announced that it has filed an
application for a patent (European Patent Office priority application:
EP15000132) on a novel method of manufacturing zoptarelin doxorubicin,
its hybrid cytotoxic molecule that is the subject of a pivotal ZoptEC
(Zoptarelin doxorubicin in Endometrial Cancer) Phase 3 clinical study in
women with advanced, recurrent or metastatic endometrial cancer who
have progressed and who have received one chemotherapeutic regimen with
platinum and taxane (either as adjuvant or first-line treatment). The
claimed manufacturing process is expected to result in a significant
reduction in the cost of goods sold, providing a stronger competitive
position for the Company. Zoptarelin doxorubicin is a complex molecule that combines a synthetic
peptide carrier with doxorubicin, a well-known chemotherapy agent. The
synthetic peptide carrier is a Luteinizing Hormone Releasing Hormone
("LHRH") agonist, a modified natural hormone with affinity for the LHRH
receptor. The design of the compound allows for the specific binding and
selective uptake of the cytotoxic conjugate by LHRH receptor-positive
tumors. Potential benefits of this targeted approach include a better
efficacy and a more favorable safety profile with lower incidence and
severity of side effects as compared to doxorubicin alone.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment